| 【Company Research】Antengene Corporation Limited (6996 HK) – Leading Asia-Pacific biopharmaceutical company developing first-in-class SINE compounds |
| 【Company Research】Xingda International (1899 HK) – Potential recovery driven by both volume and margin |
| 【Sector Research】China Property Sector – A good entry point after market over-reaction on property loan cap |
| 【Company Research】Tian Lun Gas (1600 HK) – New acquisitions to boost 2021E earnings |
| 【Fixed Income Research】Yestar – can it avert a default? (YESTHEA) |
| 【Company Research】Simcere Pharmaceutical Group (2096 HK) – Transitioning from generic to innovative |
| 【Company Research】CIMC Vehicles (Group) (1839 HK) – More catalysts in 2021E |
| 【Company Research】China Technology Sector – Global smartphone recovery to continue in 2021; Prefer share gainers and Xiaomi/Apple plays |
| 【Company Research】China Technology Sector – Time to revisit China 5G supply chain; Positive catalysts on the horizon |
| 【Company Research】InnoCare Pharma (9969 HK) – Orelabrutinib received approvals for treating r/r-CLL/SLL and r/r-MCL in China |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
